- Home
- CNA vs BMRN Comparison
CNA vs BMRN Comparison
Compare CNA & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNA
- BMRN
- Stock Information
- Founded
- CNA 1853
- BMRN 1996
- Country
- CNA United States
- BMRN United States
- Employees
- CNA N/A
- BMRN N/A
- Industry
- CNA Property-Casualty Insurers
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CNA Finance
- BMRN Health Care
- Exchange
- CNA Nasdaq
- BMRN Nasdaq
- Market Cap
- CNA 13.2B
- BMRN 11.1B
- IPO Year
- CNA N/A
- BMRN 1999
- Fundamental
- Price
- CNA $47.47
- BMRN $54.09
- Analyst Decision
- CNA Sell
- BMRN Buy
- Analyst Count
- CNA 2
- BMRN 24
- Target Price
- CNA $50.50
- BMRN $91.70
- AVG Volume (30 Days)
- CNA 385.8K
- BMRN 1.8M
- Earning Date
- CNA 11-03-2025
- BMRN 10-28-2025
- Dividend Yield
- CNA 8.08%
- BMRN N/A
- EPS Growth
- CNA N/A
- BMRN 154.69
- EPS
- CNA 3.22
- BMRN 3.40
- Revenue
- CNA $14,651,000,000.00
- BMRN $3,063,608,000.00
- Revenue This Year
- CNA N/A
- BMRN $13.32
- Revenue Next Year
- CNA $24.00
- BMRN $9.37
- P/E Ratio
- CNA $14.76
- BMRN $15.91
- Revenue Growth
- CNA 6.12
- BMRN 18.36
- 52 Week Low
- CNA $43.29
- BMRN $52.93
- 52 Week High
- CNA $51.42
- BMRN $85.00
- Technical
- Relative Strength Index (RSI)
- CNA 47.09
- BMRN 37.63
- Support Level
- CNA $46.70
- BMRN $55.99
- Resistance Level
- CNA $48.04
- BMRN $59.79
- Average True Range (ATR)
- CNA 0.62
- BMRN 1.57
- MACD
- CNA -0.30
- BMRN -0.40
- Stochastic Oscillator
- CNA 25.75
- BMRN 0.70
About CNA CNA Financial Corporation
CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.